Market Overview

UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on Limited Clinical News in 2014

Share:
Related INFI
Mid-Afternoon Market Update: GNC Gains On Upbeat Earnings; Barracuda Shares Drop
Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Earnings Miss Estimates

In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on Infinity Pharmaceuticals (NASDAQ: INFI) from Outperform to Neutral, but reiterated the $20.00 price target.

In the report, Credit Suisse noted, “We are downgrading INFI to Neutral because (1) limited clinical data is expected in 2014, (2) an increasingly complex competitive landscape, which we think is evolving to favor BTK inhibitors and ABT-199 over PI3K inhibitors; and (3) risk of class effect safety issues or drug specific safety issues, although initial concerns over infections and liver enzymes seem to have cooled down.”

Infinity Pharmaceuticals closed on Wednesday at $13.31.

Latest Ratings for INFI

DateFirmActionFromTo
Jun 2016Morgan StanleyDowngradesOverweightEqual-Weight
Jun 2016William BlairDowngradesOutperformMarket Perform
Jun 2016JefferiesDowngradesBuyHold

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Credit Suisse Jason KantorAnalyst Color Downgrades Analyst Ratings

 

Related Articles (INFI)

View Comments and Join the Discussion!